The Canadian Hemophilia Society (CHS) has formally asked the Provincial/Territorial Blood Liaison Committee to accept Canadian Blood Services’ recommendation to introduce Altuviiio (efanesoctocog alfa) for people with hemophilia A. Health Canada approved the therapy earlier this year, and national assessments have supported its clinical value. Phase 3 studies show that once‑weekly Altuviiio offers superior bleed protection, near‑normal factor VIII levels, and improvements in pain, joint health, and overall physical well‑being.
CHS and the Association of Hemophilia Clinic Directors of Canada highlight several groups who may benefit most, including those with frequent breakthrough bleeds, active lifestyles, chronic joint issues, or challenges with current treatment regimens. A provincial decision is expected soon, with potential access beginning later this spring or summer. Québec will review the therapy separately.
Read the full CHS article here: https://chscontact.ca/the-chs-urges-provinces-to-accept-cbs-recommendation-to-introduce-altuviiio/
